HK Stock Market Move | RIMAG GROUP (02522) rose more than 6% during trading, and plans to further increase its investment in Yield Genetics Co., Ltd. verifying the commercial path of medical data assetization.

RIMAG GROUP (02522) rose more than 6% during the trading session, with an increase of 4.18% to HKD 17.95 at the time of publication, with a turnover of HKD 178 million. In terms of news, recently, the company entered into a "Capital Increase Subscription Agreement" with Shanghai YingHe Medical Mait Intelligent Technology Co., Ltd. (YingHe Medical Mait) and related parties. According to this agreement, the company will subscribe to the increased registered capital of YingHe Medical Mait with a total cost of nearly one hundred million RMB. After this transaction is completed, the company's total equity stake in YingHe Medical Mait will be further increased. This capital increase and increase in shareholding ratio is an important measure for the company to implement its three-in-one strategy for medical imaging AI (medical imaging data + AI base model + imaging center scene), which is highly consistent with its long-term development plan in the medical imaging field. Tianfeng pointed out that RIMAG GROUP is a leading third-party medical imaging service platform in China, with synergy in imaging center services, imaging solutions, and Yilai Cloud. With the support of a large-scale imaging center network, the company has accumulated a high-quality medical imaging database covering more than 200 diseases and over ten million cases, with a daily increase of 20,000 to 30,000 structured data. The company has pioneered the exploration of the full process of "data resources - data assets - data transactions," and several imaging data products have been listed and traded on the data exchange. The data products have generated graded data service revenue in the state-owned platform "Data Sandbox," confirming the commercial path of medical data assets.